Overview

Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment

Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The study is designed to explore the mode of action for omalizumab therapy in patients with chronic idiopathic urticaria.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Histamine Antagonists
Histamine H1 Antagonists
Omalizumab